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Abstract
Background: The adoption in oncology of Clinical Decision Support (CDS) may help clinical users to efficiently deal with
the high complexity of the domain, lead to improved patient outcomes, and reduce the current knowledge gap
between clinical research and practice. While significant effort has been invested in the implementation of CDS, the
uptake in the clinic has been limited. The barriers to adoption have been extensively discussed in the literature. In
oncology, current CDS solutions are not able to support the complex decisions required for stratification and personalized
treatment of patients and to keep up with the high rate of change in therapeutic options and knowledge.
Results: To address these challenges, we propose a framework enabling efficient implementation of meaningful CDS that
incorporates a large variety of clinical knowledge models to bring to the clinic comprehensive solutions leveraging the
latest domain knowledge. We use both literature-based models and models built within the p-medicine project using the
rich datasets from clinical trials and care provided by the clinical partners. The framework is open to the biomedical
community, enabling reuse of deployed models by third-party CDS implementations and supporting collaboration
among modelers, CDS implementers, biomedical researchers and clinicians. To increase adoption and cope with the
complexity of patient management in oncology, we also support and leverage the clinical processes adhered to by
healthcare organizations. We design an architecture that extends the CDS framework with workflow functionality. The
clinical models are embedded in the workflow models and executed at the right time, when and where the
recommendations are needed in the clinical process.
Conclusions: In this paper we present our CDS framework developed in p-medicine and the CDS implementation
leveraging the framework. To support complex decisions, the framework relies on clinical models that encapsulate
relevant clinical knowledge. Next to assisting the decisions, this solution supports by default (through modeling and
implementation of workflows) the decision processes as well and exploits the knowledge embedded in those processes.
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Background
The large investments in the healthcare industry in improv-
ing the capabilities for data capture did not lead so far to
solutions able to efficiently deliver to the clinical users
knowledge and insight, not only disparate pieces of infor-
mation [1]. The substantial efforts dedicated to the develop-
ment of clinical models for personalization in prevention,
diagnosis and treatment are still to be leveraged in an inte-
grated, wide-scale approach in clinical care. Additionally,
coherent steps towards semantic integration of data [2],
and the implementation of high quality and comprehensive
Clinical Decision Support (CDS) systems [3, 4], are central
to achieving significant improvements in the quality of care,
while also reducing the expanding costs.
Meaningful CDS is an especially important prerequisite
for reducing the knowledge gap between clinical research
and practice in a complex genetic disease such as cancer.
Cancers are among the leading causes of morbidity and
mortality worldwide [5]. The oncology domain faces the
need for complex stratification and patient management,
for a multidisciplinary approach with coordination across
clinical specialties, and for access to large volumes of data,
information and knowledge. Current CDS solutions are
unable to support all the complex decisions required for
personalized management of cancer patients [6]. Many of
the available applications are ad-hoc, single-point solu-
tions. They become quickly obsolete and unmaintainable
due to the high rate of change in therapeutic options and
knowledge, and are hampered in their adoption by the in-
ability to meaningfully leverage the wealth of data col-
lected for each patient, and all the relevant clinical
knowledge. Adoption is limited by difficulties to integrate
these CDS systems in the healthcare environments in a
non-disruptive manner.
Driven by the need to help bridge the current knowledge
gap between research and practice, p-medicine [7, 8]
created an infrastructure supporting the transition from
current practice towards personalized medicine in oncol-
ogy. The CDS framework leverages the large datasets avail-
able in the project and the modeling efforts with the goal
to efficiently bring the new knowledge to the bedside. This
framework and its underlying solution for model storage,
management and execution is as well a platform for
(continuous) validation of existing models on new data.
The requirement to also provide support for clinical pro-
cesses and not only for clinical decisions has been dis-
cussed in literature. Next to reaching the correct diagnosis,
the diagnostic process is considered equally challenging
[9]. To support the clinical processes and to provide deci-
sion support without disrupting the current way of work-
ing, we extend our framework with workflow functionality.
In this paper we first describe our CDS framework
implemented in p-medicine and the approach to integra-
tion of knowledge models to support future-proof CDS,
i.e. systems able to grow and adapt with the rapid
growth and change of knowledge in the field. Next, we
introduce our architecture for workflow-driven CDS ex-
tending the current solution, and describe the benefits
of providing clinical workflow support to deliver recom-
mendations when and where needed along the con-
tinuum of care. The new system integrates a workflow
suite and functionality for the storage, management and
execution of clinical workflows and for the storage of
traces of execution. The knowledge models are inte-
grated and run from the workflow to support decisions
at the right point in the clinical process.
In Section II we discuss the role of a CDS system and the
key challenges to CDS implementation and adoption as
reflected in the literature, and introduce our relevant previ-
ous work. In Section III we describe the CDS framework
implemented in p-medicine and its key benefits. In Section
IV we present our CDS application implementation that
uses the framework, and its evaluation with clinical models
in two cancer types. In Section V we focus on the need to
model and provide support for clinical processes, showing
both the intrinsic benefits and the advantages for CDS. In
Section VI we summarize the key conclusions.
The role of a CDS system is to assist clinicians in mak-
ing clinical decisions relevant for a patient case. Signifi-
cant effort went to the implementation of tools for CDS in
the last few decades [9], with many solutions available
today. However, their uptake in the clinic has been limited
[6]. Current CDS solutions are faced with significant chal-
lenges that hamper their adoption. Improving the human-
computer interface, prioritizing and filtering recommen-
dations to the user, creating an architecture for sharing
executable CDS modules and services, combining recom-
mendations for patients with co-morbidities, and prioritiz-
ing CDS content development and implementation are
main aspects that need to be addressed [3].
Even when successful in the clinic, CDS solutions were
very limited in scope focusing on very specific decisions
and implementing a specific model in a particular con-
text. With the evolving understanding in the clinical
community, the evidence-based guidelines and protocols
are constantly evolving and expanding. Medical profes-
sionals often find challenging to find, study and interpret
the new scientific discoveries that may impact care. In
this context, keeping the CDS tools and their recom-
mendations up to date is a major task. In addition to the
maintenance of external knowledge and access to the
latest evidence, the ability to efficiently update the CDS
tools to take this new evidence into account and apply it
seamlessly in the clinical context has a strong impact on
adoption. Finally, fast and minimal-cost validation of the
CDS tools is essential.
Another key requirement for CDS implementations,
typically unfulfilled, is to present the recommendations
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in a way that “supports and does not interrupt the clin-
ical workflow” [3].
In [10] we introduce our approach to CDS. We report
on the implementation in the p-medicine project of the
CDS framework and of the underlying solution for stor-
age, management and execution of knowledge models.
The solution relies on clinical knowledge encapsulated in
models and has in our view many advantages compared
to building monolithic and closed CDS solutions: It is
modular, scalable, can be efficiently customized and up-
dated, and can benefit of the modeling efforts of a large
community. In this implementation we consider two im-
portant sources of models: (i) Validated knowledge de-
scribed in the literature and (ii) models derived on the
comprehensive datasets from clinical trials and care avail-
able through the p-medicine infrastructure (which can be
used in care after prospective validation). In [11] we re-
ported on the development and integration into the CDS
framework of predictive models developed by mining a
clinical trial dataset available in p-medicine. We demon-
strated that the framework enables efficient collaboration
among clinical researchers, knowledge modelers, data
miners and CDS implementers. An example of an imple-
mented literature-based model is the St. Gallen stratifica-
tion for early breast cancer [12].
Methods
We propose a CDS framework that can effectively ad-
dress several challenges related to the implementation
and adoption of decision support in healthcare. Our ob-
jectives are to bring to clinical care the knowledge
models developed in the p-medicine project, to enable
the reuse of existing models, and to keep up with new
clinical knowledge and with the development of new
models, leveraging collaboration among modelers, CDS
implementers, biomedical researchers and clinicians. In
this section we describe our solution and the key bene-
fits of this approach.
Delivering meaningful and effective CDS
With the continuous growth of medical knowledge and
with the introduction of new personalized treatments the
CDS recommendations will unavoidably need to evolve and
change. The modular approach (knowledge is encapsulated
in models with specified input/output instead of monolithic
implementation) allows the system to efficiently keep up
with introduction of new clinical knowledge in the domain.
It also allows easy reuse of models in different clinical con-
texts (e.g. models relevant for different diseases).
The solution may improve quality of care by the inclu-
sion of advanced clinical models to support decisions.
Through access to patient data, outcomes can be moni-
tored and analyzed leading to continuous validation of
the models in clinical care. The modular, light-weight
way of integrating new models into the CDS applications
lowers the threshold for adoption, and the effort of im-
plementation and maintenance.
The implementation of the CDS framework
Figure 1 depicts the overall (informal) architecture of
the CDS framework implemented in p-medicine. Next
to depicting the main component blocks of the frame-
work, we describe the environment and the context of
use of the system. The p-medicine project covers both
clinical research and clinical care contexts. The p-
medicine data warehouse aggregates the large oncology
datasets available in the project. The data are used to de-
velop models that range from predictive models derived
by data mining techniques [11] to complex multiscale
VPH models [13]. To support the complex decisions re-
quired for treating cancer patients no single model is
sufficient. A CDS solution needs to integrate all models
relevant for decisions in a disease and use them to pro-
vide recommendations at the point of care. Therefore,
we need to leverage as well knowledge generated outside
the project. To this end, we provide mechanisms for
easy integration of third party models. We implement
literature-based models that are relevant for our scenar-
ios and collaborate with the modeling community to in-
tegrate validated models developed outside the project.
While the development of the models is carried out in
the clinical research domain, the CDS framework needs to
support clinical care. The role of a CDS application is to
apply clinical models to support decisions in clinical prac-
tice. In this context, validation of the models is an essen-
tial prerequisite to their use in a clinical care context.
Models uploaded to the CDS framework are exposed
through a uniform interface to be queried by CDS appli-
cations. While we developed a CDS application in p-
medicine, by loosely coupling the CDS applications and
the model management functionality, and by providing a
uniform interface to retrieve and execute models we fa-
cilitate the use of the underlying framework by third-
party CDS implementers. This also opens the framework
to customizations of the visualization component to suit
the needs of each clinical site.
The solution facilitates continuous validation and up-
date of existing models on new datasets when those be-
come available in the p-medicine infrastructure. The
validation of individual models included in the CDS
framework can be carried out without disrupting the op-
eration of the system.
The Model Repository contains descriptions of models
(e.g. purpose, parameters), their specification (e.g. execut-
able script) and all the relevant metadata (e.g. version,
authors). The models can be either fully specified by stor-
ing in the Model Repository code that can be executed by
one of the generic engines deployed in the framework
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(e.g. Groovy [14] scripts), or specified by a reference to a
dedicated service implementing the model. New engines
can be deployed in the framework when needed.
The Model Repository Service exposes the models
metadata through the Interface Layer, and allows the
Model Runner Service to access the model specifica-
tions. The model execution is initiated from the CDS ap-
plication. When models are executed, the Model Runner
Service gets the patient data from the clinical repositor-
ies (e.g. Electronic Health Record System) or from user
input through the CDS application, and the model speci-
fication from the Model Repository Service. Next, the
Model Runner Service initiates the execution of the
model on the suitable generic Execution Engine or by
the dedicated service. The results of the model (model
output) are delivered to the CDS application and dis-
played (e.g. as a recommendation). The CDS framework
currently integrates models in the oncology domains
covered by the p-medicine scenarios [8].
Results and discussion
The CDS application implementation
Leveraging the underlying CDS framework we imple-
mented a CDS application to address the needs of the p-
medicine clinical users.
The front-end application
The application navigates the user through the phases of
patient management, retrieves and displays the patient
data, enables users to inspect, customize and run the
deployed models, and provides model descriptions and
links to relevant external information (e.g. literature,
guidelines).
As seen in Fig. 2, the application includes first steps
towards supporting clinical processes by distinguishing
several phases of patient management: data review, diag-
nosis, treatment selection; models are incorporated in
the relevant stage and the information flow between
stages is supported.
Models are selected by moving them from the right
panel to the left panel to be instantiated with the rele-
vant patient data (from the patient file or user input),
and applied for the current patient. The clinician can
accept or override the model recommendation. The rec-
ommendation appears in the corresponding box and can
be extended by the clinician and saved to the patient file.
Recommendations and decisions are persisted by the
tool for evaluation (of both tool and models), analysis,
and quality monitoring.
Figure 3 shows the treatment selection screen including
a range of treatment models and medication templates.
The clinician selects the suitable treatment models. Based
on the results of the models applied in diagnosis phase the
system may suggest specific treatment models as applic-
able. Recommendations of the treatment models may refer
to the most effective treatment for this patient, safety risks,
comparisons of different treatments, etc. The medication
templates can be modified, further specified e.g. with spe-
cific substances or detailed doses and ways of administra-
tion, and saved for future reuse. They are moved to the left
panel to be instantiated with patient data and prescribed.
Fig. 1 Architecture and context of use of the CDS framework
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Evaluation scenarios
We evaluated the CDS (front-end) application imple-
mentation and the underlying framework in scenarios in
two diseases of focus in p-medicine, breast cancer and
nephroblastoma. In each scenario, relevant knowledge
models (developed in p-medicine or selected from litera-
ture) addressing diagnosis and treatment selection were
deployed in the CDS framework and integrated in the
CDS application.
We previously demonstrated the ease of deployment
of new models into the framework [15]. In this evalu-
ation the focus was on evaluating the efficiency of build-
ing a CDS application providing meaningful support
that uses the framework and incorporates deployed
models. The scenarios were defined with the clinical
users in the project and the CDS application was well re-
ceived by the clinicians in the two clinical domains. This
evaluation has shown the feasibility of the overall
approach as well: Both model integration in the CDS
application and model deployment in the framework
require relatively low implementation effort. Models can
be easily replaced and updated, reused, and combined.
p-medicine knowledge models
In this section we describe several p-medicine models
that have been deployed in the CDS framework and used
to evaluate the CDS application implementation and the
framework.
In future work, the models will be prospectively vali-
dated with new data in the context of clinical studies.
The CDS application and the underlying framework will
support the efficient execution of the models with the
new patient data and preserve the results. Next to valid-
ating the model, this allows to demonstrate the ability of
the framework to support the efficient (continuous) val-
idation of the models.
The Oncosimlator models
The objective of the Oncosimulator is to simulate the re-
sponse of clinical tumours to specific treatment schemes
and/or schedules in patient individualized context [13]. In
the CDS system, the Oncosimulator is represented by two
branches addressing breast cancer and nephroblastoma.
The breast cancer branch deals with the paradigm of
anti-angiogenic treatment and specifically of single-agent
bevacizumab therapy. A continuum approach describing
vascular tumour growth under angiogenic signaling has
been developed based on relevant literature [16] and
bevacizumab pharmacokinetic properties have been in-
corporated [17]. In particular, the model consists of a pair
of ordinary differential equations reflecting the interplay
between tumour volume and carrying capacity i.e. the
maximal tumour volume that the current vascular system
can support. The nephroblastoma Oncosimulator model
[18, 19] is a predominantly discrete, clinically-oriented
multiscale cancer model simulating the tumor response to
preoperative chemotherapy schemes based on the SIOP
Fig. 2 Diagnosis screen
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clinical trial. Different scenarios have been formulated ad-
dressing specific clinical questions. From these scenarios,
three have been selected for CDS integration, two utilizing
the breast cancer model and one utilizing the nephroblas-
toma model.
The integration of the Oncosimulator models is based
on publishing models as dedicated engines. As the two
branches were implemented in different programming
languages, the models were incorporated in a wrapper to
achieve the required integration and build the services.
For each Oncosimulator branch a different procedure of
transformation and integration was followed (Fig. 4).
The breast cancer branch is developed in MATLAB, as a
master script, calling a number of functions. Therefore,
by utilizing the MATLAB Compiler, the model was
recompiled into an executable java jar, with its main
runner class being mapped to the master script. The jar
was finally included in the wrapper’s Maven repository.
The nephroblastoma branch, written in C ++, was
recompiled in a form of shared library using the Java
Native Interface, by changing its main function into a
function which communicates with the wrapper code
Fig. 3 Treatment selection screen
Fig. 4 CDS integration of breast and nephroblastoma branches
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through a header file. Both procedures produce corre-
sponding wsdl files, which describe the web services.
To demonstrate the integration of the Oncosimulator
into the CDS system, an indicative CDS scenario on
breast cancer, addressing an actual clinical question re-
garding the impact of applying fractionated versions of
an original treatment scheme on the treatment outcome,
is outlined below. The clinician selects the correspond-
ing model (breast cancer scenario) and sets values to
user generated input parameters (treatment schema)
(Fig. 5). By pressing run, a request is called to the remote
service. The request is sent to the URL of the remote
machine where the model was published, together with
the necessary input data. Based on the input data, a file
is created (csv for breast cancer, xml for nephroblas-
toma), which serves as input to the model. After the exe-
cution is completed, the output files are saved into the
remote machine and a predefined set of results depicting
clinically important information (the required set of bio-
logical values, along with a graph depicting the tumor
evolution over time), are sent as response and shown in
the CDS’s GUI (Fig. 6).
The scenario is presented via an exemplar case study
based on a model instance already developed using
time-course data derived in the context of in vivo exper-
iments studying the anti-tumour efficacy of bevacizumab
in higher mammalian species (Mus musculus). The way
that the clinician interacts with the system is sufficiently
generic and as such will not be affected by the substitu-
tion of this model instance with another referring to
human patient cases and which is currently under re-
finement. The details of both the original and the frac-
tionated version of the scheme appear in Fig. 5.
Even though the treatment schemes did not induce
tumour regression for the specific tumour, tumour
growth inhibition (i.e. comparing to the tumour evolu-
tion in the case of untreated growth) has been achieved
for both cases. In particular, as it is shown in Fig. 6, the
original treatment scheme (blue line) has induced a
tumour growth inhibition percentage equal to 73.6 %
while the fractionated one (green line) has prompted a
tumour growth inhibition percentage equal to 79.5 %
(calculated as the percentage of change in tumour vol-
ume in the treatment module simulation with respect to
the free growth module simulation, at the end of the
treatment cycle). Hence, the superiority of the fraction-
ated scheme comparing to the original scheme would be
revealed to the user along with the implied statement
that none of the applied modes of administration would
induce tumour regression.
miRNA model for nephroblastoma
MicroRNAs (miRNA) have been implicated in a number
of diseases, including cancer, and dysregulation of them
has been widely observed in different stages of cancer
[20, 21]. The regulation of miRNAs can result in post-
transcriptional down-regulation or up-regulation of the
expression of certain genes [22], which subsequently
affect other genes downstream in gene regulatory net-
works (GRNs) or biological processes. Taking into ac-
count miRNA expression data from a patient and GRNs
knowledge, the treating physician may select targeted
drugs for personalized treatment to improve efficiency
and increase quality of care.
The miRNA pathway analysis model was incorporated
in the CDS framework to support the evaluation in the
nephroblastoma scenario. During diagnosis, the miRNA
model supports the non-intrusive early identification of
nephroblastoma patients among the tested subjects. The
model was created using a public miRNA dataset includ-
ing 23 nephroblastoma patient samples (prior to chemo-
therapy) and 19 healthy controls [23] (GSE38419) in
conjunction with the human pathways from the KEGG
database [24]. The model identifies the targeted/dis-
rupted genes from the miRNA expression data and using
the MinePath pathway analysis system [25] extracts the
functional and nonfunctional sub-paths of the healthy
and diseased samples. Finally, a predictive model using
Fig. 5 Details of two simulated bevacizumab monotherapy schemes (dosage, frequency of administration and timepoints of administration). The
treatment scheme details are extracted from European medicines agency (Avastin, INN - bevacizumab - WC500029271.pdf) and constitute the
two suggested modes of bevacizumab administration for metastatic breast cancer
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the C4.5 decision tree algorithm [26] on the functional
status of the sub-paths is created. More details of the
model including setup and algorithmic steps are de-
scribed in [27]. The assessed performance of the predict-
ive model is 80 % for 10-fold cross-validation, and 78 %
for leave one out cross validation.
The decision tree highlighted three key sub-paths in-
cluding hub genes (highly connected genes) in signaling
pathways, able to discriminate between nephroblastoma
and healthy subjects. Specifically, in the GnRH signaling
pathway the sub-path PLCβ→ PKC β→MEKK has
been selected as significant for the healthy population,
an outcome which is in accordance to the literature
since the protein kinase C (PKC) is implicated in the
regulation of neuroblastoma [28]. The sub-paths PDK1
β→AKT β→ CREB in the PI3K-AKT signaling pathway
and the P50 β→COX2 in NF-KAPPA B pathway have
been also selected as significant for the model, which are
known as regulators for neuroblastoma cell survival [29]
and proliferation [30] respectively.
Workflow-driven CDS
In this Section we introduce our novel approach to CDS
provision which supports both the clinical decisions and
the clinical processes. The workflow-driven CDS frame-
work builds on the CDS framework described in Section
III and extends it with capabilities for workflow modeling,
management and execution. For each clinical domain of
relevance, the clinical processes for the specialists involved
in care provision are modeled and implemented in the
framework. Clinical knowledge models are incorporated
in the workflows to provide recommendations at the right
decision points within the clinical processes.
Healthcare organizations deploy and adhere to well-
defined clinical processes developed and optimized over
time, derived from evidence, and based on the clinical
guidelines and protocols built by the clinical community
to ensure that the best care is provided. Studies have
shown that in oncology treatment according to an estab-
lished protocol assures the best available care for a pa-
tient [31]. Such protocols have been widely implemented
in clinical care and often customized to the local context
of each clinical site. We formalize clinical processes
into clinical workflows, which can be modeled and opti-
mized. We use open source tools previously developed for
business processes such as jBPM [32], leveraging the Busi-
ness Process Model and Notation (BPMN) standard [33].
In the rest of the section we discuss the relevance of
workflow support for CDS, then we briefly describe our
workflow-driven CDS framework (detailed in [13]).
Relevance of clinical workflows for CDS implementation
Deployed clinical processes include both explicit know-
ledge (e.g. rules and tasks derived from protocols or spe-
cific to the local hospital context), and implicit information
captured in their implementation within a healthcare
organization. When leveraging the clinical processes a
CDS solution benefits of all the knowledge, both explicit
and implicit.
Integrating CDS functionality in the established pro-
cesses can help address the complexity of personalized pa-
tient management along the entire care continuum in a
flexible and scalable way. This approach enables seamless
integration in the clinical environment and cost-effective
adaptation and customization. Adherence to the local
Fig. 6 Tumour volume time evolution for a tumour treated with bevacizumab according to a treatment scheme consisting of the administration of
15 mg/kg of bevacizumab as a single-agent, once every three weeks for a total of 4 doses (blue line) and a fractionated version of the aforementioned
treatment scheme consisting of the administration of 10 mg/kg of bevacizumab as a single-agent, every other week for a total of 6 doses (green line)
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clinical processes leads to a low adoption barrier for the
CDS by avoiding disruption of the way of working. Build-
ing decision support that does not interrupt the clinical
workflow has been identified as an important factor for the
success of a CDS solution [3]. Driving the CDS provision
from the clinical workflows also facilitates dissemination of
best practices and of the newest protocols and knowledge,
as it enables clinical sites to efficiently share workflows, en-
rich them, and customize them for local needs.
Workflow-driven CDS framework
To support efficient decision making in complex clinical
scenarios, such as those driving care delivery in oncology
that involve several specialists and a large number of in-
terrelated and coordinated steps, we model and imple-
ment the clinical processes that underlie each scenario.
We build a dynamic system able to provide for each pa-
tient the right recommendation at the right time to the
right clinical specialist.
We propose a modular approach allowing for efficient
extensions to new clinical domains. For each relevant
disease we define modules corresponding to coordinated
care processes (e.g. protocols) and represent the work-
flows of all specialists involved (e.g. oncologist, nurse,
pathologist) and their interactions. These multispecialty
workflow modules are stored in the Workflow Models
Repository. We also represent customizations designed
by the healthcare organizations and build mechanisms
for handling deviations from the defined processes (e.g.
to handle cases when the standard protocol is not ap-
plicable or an exception has occurred).
Each workflow module has its own specific decision
support needs which we support by incorporating suit-
able knowledge models at the right steps. The frame-
work facilitates multi-site collaboration as well and
supports alternative workflows in each module. Devia-
tions from the specified workflows are stored, managed
and analysed to help improve the clinical processes.
Fig. 7 Simplified workflow for early Breast Cancer involving several specialists and departments. The workflow is represented using BPMN [20]
Bucur et al. BMC Medical Informatics and Decision Making 2016, 16(Suppl 2):87 Page 159 of 162
Changes to clinical workflows and to the knowledge
models can be efficiently implemented. This solution de-
livers scalability both with respect to workflows defin-
ition and to deployment of knowledge models.
Figure 7 depicts a simplified workflow for the manage-
ment of early breast cancer according to the St. Gallen
guidelines [12]. Several specialists are involved with spe-
cific clinical processes: treating physician/oncologist,
pathologist, radiologist, laboratory (technician). We rep-
resent tasks, decision points, models executed in those
decisions points to generate recommendations, and the
interactions among the clinical experts. In the example,
a patient is assessed by the oncologist and a radiology
examination is ordered. If no suspected lesion is
identified the workflow stops. Otherwise, pathology diag-
nosis is ordered. If the diagnosis is negative the process
ends. Otherwise, the results are fed into the St. Gallen
model to stratify the patient. Applying the St. Gallen
guidelines, for several disease subtypes the oncologist or-
ders an additional test (Oncotype DX [34]) performed by
a dedicated lab. Combining the results, the oncologist
plans the therapy.
Figure 8 depicts the overall architecture of the work-
flow-driven CDS framework. When providing support for
a specific patient case, the suitable workflow module is re-
trieved from the Workflow Models Repository. The work-
flow models in this module will be executed by engines
deployed in the workflow environment (e.g. locally at the
Fig. 8 The overall architecture of the workflow-driven CDS framework
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healthcare organization). A set of workflow suites may be
evaluated to select the most suitable components (en-
gines, editors, etc.) for each deployment. For the initial im-
plementation we have selected jBPM due to its adoption
and open source license.
Executed workflow instances are persisted to be used
to evaluate the performance of the system, the quality of
the recommendations and the users’ behaviour and
interaction with the system. The aggregation and ana-
lysis of the clinical process data can provide significant
insights that go beyond the clinical processes alone, hav-
ing as well the potential to improve the outcomes and
the quality of care. For workflow execution the frame-
work relies on several services that retrieve and run rele-
vant clinical models as described in Section III.
Conclusions
In this paper we present our CDS framework developed in
p-medicine and the CDS implementation leveraging the
framework. To support complex decisions, the framework
relies on clinical models that encapsulate relevant clinical
knowledge. The p-medicine project builds a range of such
models of various complexity and we have also imple-
mented literature-based models.
Our solution was designed to provide flexibility and
enable keeping up with the steep growth and change of
clinical knowledge in oncology. The CDS application im-
plementation allowed to demonstrate the capabilities of the
framework. We evaluated it in two clinical scenarios in
breast cancer and nephroblastoma, applying both know-
ledge models developed in p-medicine and literature-based.
Further, we extended this framework to leverage and
support the established clinical processes. Next to the
traditional business processes, healthcare environments
have their specific clinical processes (often based on
clinical protocols that are customized to fit the local
context). We model and implement these processes as
clinical workflows that drive CDS provisioning. Imple-
menting the clinical processes we lower the adoption
barrier of the CDS solution, and exploit the implicit and
explicit knowledge contained in these processes to pro-
vide better decision support.
This loosely-coupled solution allows to customize for
each healthcare organization both the clinical processes
and the knowledge models applied for decision support.
The approach also enables efficient management of up-
dates to the clinical models to reflect the latest clinical
knowledge and to the clinical workflows to apply the
most recent clinical guidelines and protocols.
The traces of workflow execution can provide much
needed insights concerning existing clinical processes and
their implementation. These data can be used to evaluate
adherence to established processes and to identify frequent
deviations, safety risks, errors, and performance bottlenecks.
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